Retatrutide vs Semaglutide: What the Clinical Trial Data Shows

This page summarizes published clinical research. All Magnolia RL products are for in vitro research use only and are not intended for human use.

Semaglutide (the active compound in Ozempic and Wegovy) has dominated the GLP-1 research conversation since 2021. But a newer investigational compound — Retatrutide — has produced clinical trial results that have drawn significant attention from the research community. This article summarizes the published data comparing these two compounds across efficacy, mechanism of action, and trial outcomes.

What Each Compound Is

Semaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone to enhance insulin secretion and suppress appetite. It has been FDA-approved under the brand names Ozempic (diabetes management) and Wegovy (weight management).

Retatrutide (LY3437943) is an investigational compound developed by Eli Lilly. It is a triple agonist — it activates GLP-1 receptors, GIP receptors (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. No other compound currently in clinical development combines all three of these mechanisms in a single molecule. Retatrutide is not FDA-approved and remains in Phase 3 trials as of 2026.

Mechanism Comparison

The key differentiator is glucagon receptor activation — it raises basal metabolic rate and promotes hepatic fat oxidation, directly counteracting the metabolic adaptation that limits outcomes with GLP-1-only compounds.

Phase 2 Trial Data

The landmark Phase 2 retatrutide trial was published in the New England Journal of Medicine in 2023 (Jastreboff et al.), enrolling adults with obesity (BMI ≥30) over 48 weeks.

For context, semaglutide 2.4mg (Wegovy) produced approximately 14.9% weight reduction in its pivotal STEP 1 trial at 68 weeks. Key findings: 100% of participants on 8mg and 12mg achieved at least 5% weight reduction; women on 12mg averaged 29.0% body weight reduction; liver fat content decreased by more than 80% in high-dose cohorts.

Phase 3 Data (2025)

Phase 3 TRIUMPH-4 trial results confirmed and extended the Phase 2 findings over 68 weeks: Retatrutide 12mg achieved 28.7% average body weight reduction — the largest average weight reduction reported in any Phase 3 trial of an anti-obesity compound to date, compared to semaglutide's 14.9% and tirzepatide's approximately 20–22%.

Side Effect Profile

Both compounds share a similar gastrointestinal side effect profile — nausea, vomiting, and diarrhea — occurring primarily during dose escalation. Retatrutide Phase 2 reported no severe hypoglycemia and no serious treatment-related adverse events in participants without diabetes. The safety profile was described as comparable to GLP-1 agonists when properly titrated.

Where Research Stands in 2026

Eli Lilly's TRIUMPH Phase 3 program includes multiple ongoing trials. If results continue to confirm Phase 2 findings, regulatory submissions to the FDA could follow in late 2026 or 2027. Commercial availability, if approved, would likely not precede 2027–2028.

Sources: Jastreboff et al., NEJM 2023 (Phase 2); TRIUMPH-4 Phase 3 data, 2025; STEP 1 semaglutide trial (Wilding et al., NEJM 2021). All Magnolia RL products are for in vitro research use only.